Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    UCSF-CAPRA Score for Prostate Cancer Risk

    Predicts outcomes of patients post-treatment for prostate cancer.
    Favorite
    Pearls/Pitfalls

    A prognostic score for prostate cancer, incorporating both the PSA and Gleason Score, designed to be both simple but with an accuracy comparable with the best nomograms.

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    • For very low risk patients, consider routine surveillance.
    • For low to intermediate-risk patients, consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy).
    • For intermediate to high-risk patients, consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy).
    • For very high-risk patients, consider either multimodal therapy OR hormonal therapy, and clinical trial enrollment.

    Formula

    Addition of the selected points.

    Facts & Figures

    Score interpretation:

    Metastasis-free interval
    % likelihood (95% CI)
    Prostate cancer–specific survival
    % likelihood (95% CI)
    Overall survival
    % likelihood (95% CI)
    CAPRA Risk Group 5-year 10-year 5-year 10-year 5-year 10-year
    Low Risk Group (0-2 points) 99.3 (98.8 to 99.5) 97.5 (95.9 to 98.5) 99.7 (99.9 to 99.5) 97.1 (98.2 to 95.1) 92.5 (91.5 to 93.5) 71.4 (67.8 to 74.7)
    Intermediate Risk Group (3-5 points) 96.9 (96.2 to 97.5) 93.3 (91.7 to 94.6) 98.6 (99.0 to 98.1) 91.6 (93.4 to 89.5) 90.2 (89.0 to 91.3) 59.7 (56.7 to 62.7)
    High Risk Group (≥6 points) 90.4 (88.4 to 92.0) 83.4 (79.6 to 86.6) 93.4 (94.9 to 91.5) 79.1 (83.1 to 74.3) 78.7 (75.9 to 81.2) 42.0 (37.4 to 46.5)

    For more detailed risk outcomes, see Cooperberg 2009.

    Literature

    Validation

    Research PaperZhao KH, et al. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology, 2008. 72(2): p. 396-400.Research PaperMay M, et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients. J Urol, 2007. 178(5): p. 1957-62; discussion 1962.Research PaperCooperberg MR, et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer, 2006. 107(10): p. 2384-91.Research PaperCooperberg MR, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol, 2005. 173(6): p. 1938-42.
    Dr. Matthew R. Cooperberg

    About the Creator

    Matthew R. Cooperberg, MD, MPH, is an associate professor of urology and epidemiology/biostatistics at UCSF. He practices on the urologic oncology team of the UCSF Helen Diller Family Comprehensive Cancer Center, Mount Zion Medical Center and also operates at San Francisco General Hospital. Dr. Cooperberg researches primarily prostate cancer with a focus on effectiveness of emerging biomarkers on diagnosis and risk assessment, and relative benefits of treatment strategies on cost effectiveness and quality of life.

    To view Dr. Matthew R. Cooperberg's publications, visit PubMed